CANCER THERAPEUTIC DRUG EG12014 IS APPROVED FOR PHASE III CLINICAL TRIAL
EirGenix's biosimilar drug EG12014 has been approved by US Food and Drug Administration (FDA) and Taiwan Food and Drug Administration (TFDA) for Phase III clinical trial. It is estimated to recruit 800 breast cancer patients around the world for the trial. According to Roche's 2017 annual report, Herceptin's global sales amounted to 7.014 billion Swiss francs. This trial will be a large-scale international one for biosimilar drug in Taiwan in recent years. This trial will increase the competitiveness of drug development in Taiwan.